BEAM
Beam Therapeutics Inc.
Key Financials
Operating Income
$-383693000
↑ 7.7%
Net Income
$-79992000
↑ 78.8%
Revenue
$139.7M
↑ 120.0%
EPS (Diluted)
$-0.81
↑ 82.3%
Total Assets
$1.5B
↑ 34.2%
Shareholders' Equity
$1.2B
↑ 68.8%
Cash & Equivalents
$294.9M
↑ 4.6%
Total Liabilities
$242.8M
↓ 34.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/8/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| SCHEDULE 13G | 4/29/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BEAM |
| Company Name | Beam Therapeutics Inc. |
| CIK | 1745999 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 857-327-8775 |